Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

How did US-China tariff cuts impact oil prices? Why did Hong Kong stocks surge on trade news? What caused Tesla stock to jump premarket today? How will Trump’s drug price order affect pharma? Why is Nvidia facing its first Wall Street sell rating? What’s behind Berkshire Hathaway’s CEO transition? How are small businesses coping with Trump’s tariffs? Why is Walmart changing its food court strategy? What’s driving the rise in Bitcoin and crypto inflows?

Eli Lilly's Zepbound Shows Superior Weight Loss Over Novo Nordisk's Wegovy In Head-To-Head Trial

benzinga.com/25/05/45341500/eli-lillys-zepbound-shows-superior-weight-loss-over-novo-nordisks-wegovy-in-head-to-head-trial

Eli Lilly and Company’s (NYSE:LLY) Zepbound demonstrated superior weight reduction compared to Novo Nordisk A/S’s (NYSE:NVO) Wegovy in a 72-week head-to-head trial.
What Happened: Participants treated with tirzepatide (Zepbound) achieved an average weight loss of 20.2%, compared to 13.7%…

This story appeared on benzinga.com, 2025-05-12 08:03:59.